Skip to main content

Lexicon Pharmaceuticals Value Stock - Dividend - Research Selection

Lexicon Pharmaceuticals

ISIN: US5288723027, WKN: A14SSK

Market price date: 22.01.2021
Market price: 8,51 USD




Lexicon Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 14-03-2020
Cash flow
Net operating cash flow 113.807.000
Capital Expenditures -70.000
Free cash flow 113.737.000
Balance sheet
Total Equity 117.101.000
Liabilities & Shareholders equity 417.715.000
Income statement
Net income 130.133.000
Eps (diluted) 1,110
Diluted shares outstanding 117.237.000
Net sales/revenue 322.070.000

Fundamental ratios calculated on: 22-01-2021

Ratios
Key figures 22-01-2021
Cash flow
P/C 8,77
   
P/FC 8,77
Balance sheet
ROI31,15
ROE28,03
Income statement
P/E7,67
Div. Yield0,00%
P/B8,52
P/S3,10


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolLXRX
Market Capitalization994.169.728,00 USD
CountryUnited States
IndicesNASDAQ Comp.
SectorsPharma
Raw Data SourceUS GAAP in Millionen USD
Stock Split2015-05-21,1.0000/7.0000
Internetwww.lexgen.com


Description of the company

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.lexgen.com